Chemotherapy-Induced Anemia Market Size was valued at USD 2.4 Bn in 2023 and is predicted to reach USD 3.9 Bn by 2031 at a 6.5% CAGR during the forecast period for 2024-2031.
Chemotherapy induces anemia, a disorder characterized by decreased hemoglobin and red blood cells. This disease originates from the fast cell division that chemotherapy treatments frequently target. The market is being propelled primarily by the increasing recognition of the significance of anemia management in cancer therapy among both healthcare providers and patients. In addition, the availability of erythropoiesis-stimulating medicines and iron supplements has increased the need for therapies for chemotherapy-induced anemia, which in turn has boosted the growth of the chemotherapy-induced anemia market. Furthermore, market expansions are being propelled by the development of novel therapies, which in turn are being supported by rising investments in cancer research initiatives from governments, private organizations, and pharmaceutical companies, as well as by continuously improving research technologies. In addition, cancer patients’ quality of life has prompted oncologists to place a greater emphasis on effective chemotherapy-induced anemia.
However, the market's expansion is hindered by the stringent regulatory standards of chemotherapy-induced anemia, and creating therapy, researching, and developing strategies to target chemotherapy-induced anemia is a time-consuming and expensive endeavor. In addition, the market expansion is also hindered by the negative effects linked to chemotherapy-induced anemia therapies. Furthermore, factors driving market expansion include an uptick in cancer cases and fatalities globally and a surge in research and development efforts related to the creation of these medications. Chemotherapy-induced anemia is in high demand because cancer rates are increasing globally.
The chemotherapy-induced anemia market is segmented based on a type of anemia, treatment type, drug type, and end-user. Based on anemia, the market is segmented into mild anemia, moderate anemia, severe anemia, and life-threatening anemia. By treatment type, the market is segmented into RBC transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation. By drug type, the market is segmented into epogen injection, procrit injection, androxy oral, Aranesp injection, epoetin alfa injection, and others. By end-user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.
The mild anemia market in chemotherapy-induced anemia is expected to hold a major global market share in 2023. This is because treating mild anemia, a common side effect among chemotherapy patients, is essential for curative cancer treatment and quality of life maintenance. Because of its ubiquity and the fact that it is in its early stages, mild anemia is more frequently diagnosed and treated than moderate cases.
Hospitals are growing rapidly in the chemotherapy-induced anemia market because they treat a large number of cancer patients through chemotherapy, and many of these patients experience anemia as a side effect. Hospitals offer access to cutting-edge diagnostic techniques and specialized cancer care, making more precise diagnoses and individualized plans for managing anemia possible. The increasing focus on enhancing the well-being of cancer patients has prompted hospitals to place a premium on excellent chemotherapy-induced anemia management, which has contributed to their fast expansion in this sector.
The North American chemotherapy-induced anemia market is expected to register the highest market share in revenue in the near future. It can be attributed to the focus on establishing targeted treatments, elevated cancer rates, and a dramatic rise in public understanding of cancer prevention and treatment options. The rising need for therapies for chemotherapy-induced anemia is also fueling the expansion of this industry. In addition, Asia Pacific is anticipated to grow rapidly in the global chemotherapy-induced anemia market due to the region's vast population and the growing need for top-notch healthcare, the growing number of older adults, and the subsequent demand for better healthcare services and the need for cutting-edge medical technology.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 2.4 Bn |
| Revenue Forecast In 2031 | USD 3.9 Bn |
| Growth Rate CAGR | CAGR of 6.5% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Anemia, By Treatment Type, By Drug Type, By End-user and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Astellas Pharma Inc., Blausen Medical, Dr. Reddy’s Laboratories Ltd., Elsevier Inc., F. Hoffmann-La Roche Ltd, FibroGen, Inc., GlaxoSmithKline PLC, Healio, Johnson & Johnson, Karger AG, Novartis AG, and Pfizer Inc. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chemotherapy-Induced Anemia Market-By Type of Anemia
Chemotherapy-Induced Anemia Market-By Treatment Type
Chemotherapy-Induced Anemia Market-By Drug Type
Chemotherapy-Induced Anemia Market-By End-User
Chemotherapy-Induced Anemia Market-By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.